{"url_path":"/sec/derm/8-k/2026-05-13/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1867066/0001104659-26-060232-index.html","accession_number":"0001104659-26-060232","cik":"0001867066","ticker":"DERM","issuer_name":"Journey Medical Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/1867066/0001104659-26-060232-index.html","primary_entity_key":"0001867066","primary_entity_name":"Journey Medical Corp"},"word_count":290,"has_tables":true,"body_markdown":"false\n0001867066\n\n0001867066\n\n2026-05-13\n2026-05-13\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**WASHINGTON, D.C. 20549**\n\n \n\n \n\n**FORM 8-K**\n\n \n\n \n\n**CURRENT REPORT**\n\n \n\n**Pursuant to Section 13 or 15(d) of the\nSecurities Exchange Act of 1934**\n\n \n\nDate of Report (Date of earliest event\nreported): May 13, 2026\n\n \n\n**Journey Medical Corporation**\n\n(Exact Name of Registrant as Specified in Charter)\n\n \n\nDelaware \n001-41063 \n47-1879539\n\n(State or Other Jurisdiction\nof Incorporation) \n(Commission File Number) \n(I.R.S.\nEmployer\n\nIdentification No.)\n\n \n\n**9237 E Via de Ventura Blvd., Suite 105**\n\n**Scottsdale, AZ 8525**\n\n(Address of principal executive offices)\n\n \n\nRegistrant’s telephone number, including\narea code: **(480) 434-6670**\n\n \n\nCheck the appropriate box below if the Form\n8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n \n\n¨Written communications pursuant to Rule 425 under the Securities\nAct (17 CFR 230.425)\n\n  \n\n¨Soliciting material pursuant to Rule 14a-12 under the Exchange\nAct (17 CFR 240.14a-12)\n\n  \n\n¨Pre-commencement communications pursuant to Rule 14d-2(b) under\nthe Exchange Act (17 CFR 240.14d-2(b))\n\n  \n\n¨Pre-commencement communications pursuant to Rule 13e-4(c) under\nthe Exchange Act (17 CFR 240.13e-4(c))\n\n \n\n**Securities registered\npursuant to Section 12(b) of the Act:**\n\n \n\n**Title\nof each class**\n**Trading\nSymbol(s)**\n**Name\nof each exchange\non which registered**\n\nCommon Stock\nDERM\nThe Nasdaq Capital Market\n\n \n\nIndicate by check mark whether the registrant\nis an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the\nSecurities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging growth company   x\n\n \n\nIf an emerging growth company, indicate by check\nmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting\nstandards provided pursuant to Section 13(a) of the Exchange Act. ¨"}